Investigators trialed injection of an immune-stimulating substance (poly-ICLC) into the prostate gland using MRI-ultrasound fusion technology in patients scheduled to undergo radical prostatectomy.

Complete Response in all treated lesions: Patients completing the study showed CR via the MD Anderson Criteria and RECIST v1.1 with no active tumor detected on MRI First-of-its-kind single ...

BEVERLY HILLS, Calif., Nov. 10, 2025 /PRNewswire/ -- Williams Cancer Institute ("WCI"), a leading center pioneering the use of intratumoral immunotherapy for late-stage cancer patients, announced that ...

Procedure considerations for image-guided intratumoral immunotherapy: A retrospective study of 357 cases. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Underinvested, Under-Referred, and Underserved: Applying a Gender Equity Continuum Framework in Cancer Control Continuum Programs and Policies to Expand to Transgender and Nonbinary Populations Ad/PNP ...

Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders ...

The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safety The manuscript is ...